转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Nature：一种多发性硬化疾病的新疗法

2013-10-21 Nature中文网 Nature中文网

多发性硬化疾病新疗法
关注

Peter Schultz 及同事用大鼠“少突胶质前体细胞” (OPC) 对在体外能增强OPC分化的小分子进行了一次高吞吐量的、基于图像的筛选。利用该方法，他们识别和定性了在多发性硬化等疾病中能促进基于少突细胞的髓鞘再生的小分子。他们识别出的主要化合物是“苯托品”，一种获准用于帕金森氏症治疗的药物。“苯托品”在活体中对两个“脱髓鞘作用”疾病模型有效，同时对免疫系统没有可以测得到的影响。原文检索De

Peter Schultz 及同事用大鼠“少突胶质前体细胞” (OPC) 对在体外能增强OPC分化的小分子进行了一次高吞吐量的、基于图像的筛选。利用该方法，他们识别和定性了在多发性硬化等疾病中能促进基于少突细胞的髓鞘再生的小分子。他们识别出的主要化合物是“苯托品”，一种获准用于帕金森氏症治疗的药物。“苯托品”在活体中对两个“脱髓鞘作用”疾病模型有效，同时对免疫系统没有可以测得到的影响。

原文检索

Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, Padmanabhan K, Swoboda JG, Ahmad I, Kondo T, Gage FH, Theofilopoulos AN, Lawson BR, Schultz PG, Lairson LL.A regenerative approach to the treatment of multiple sclerosis.Nature. 2013 Oct 17.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879705, encodeId=0e5218e970570, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 03 11:38:00 CST 2014, time=2014-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889578, encodeId=639418895e8ce, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 13 05:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554426, encodeId=1f6c155442645, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Oct 23 01:38:00 CST 2013, time=2013-10-23, status=1, ipAttribution=)]
    2014-03-03 liye789132251

    #Nat#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1879705, encodeId=0e5218e970570, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 03 11:38:00 CST 2014, time=2014-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889578, encodeId=639418895e8ce, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 13 05:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554426, encodeId=1f6c155442645, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Oct 23 01:38:00 CST 2013, time=2013-10-23, status=1, ipAttribution=)]
    2014-02-13 jml2009

    #多发性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1879705, encodeId=0e5218e970570, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Mar 03 11:38:00 CST 2014, time=2014-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889578, encodeId=639418895e8ce, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Feb 13 05:38:00 CST 2014, time=2014-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1554426, encodeId=1f6c155442645, content=<a href='/topic/show?id=74e458559f5' target=_blank style='color:#2F92EE;'>#新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58559, encryptionId=74e458559f5, topicName=新疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03114536414, createdName=kcb074, createdTime=Wed Oct 23 01:38:00 CST 2013, time=2013-10-23, status=1, ipAttribution=)]
    2013-10-23 kcb074

    #新疗法#

    0